ECSP056232A - Nuevos compuestos - Google Patents
Nuevos compuestosInfo
- Publication number
- ECSP056232A ECSP056232A EC2005006232A ECSP056232A ECSP056232A EC SP056232 A ECSP056232 A EC SP056232A EC 2005006232 A EC2005006232 A EC 2005006232A EC SP056232 A ECSP056232 A EC SP056232A EC SP056232 A ECSP056232 A EC SP056232A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- aryl
- group
- het
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000966 norepinephrine reuptake Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000000697 serotonin reuptake Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de fórmula (I) y sus derivados farmacéutica y/o veterinariamente aceptables, en la que R1 es un átomo de H, un grupo alquilo de C1-6, un grupo -C(X)Y, un grupo cicloalquilo de C3-8, un grupo arilo, un grupo het, un grupo arilo-alquilo de C1-4, o un grupo het-alquilo de C1-4, en el que los grupos cicloalquilo, arilo o het están opcionalmente sustituidos por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-8, alcoxi de C1-8, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; R2 es un grupo arilo o heteroarilo, cada uno opcionalmente sustituido por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-8, alcoxi de C1-8, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; R3 es un grupo alquilo de C1-6, cicloalquilo de C3-8, cicloalquilo de C3-8-alquilo de C1-6, arilo, het, arilo-alquilo de C1-4 o het-alquilo de C1-4, en el que los grupos cicloalquilo, arilo o het están opcionalmente sustituidos por al menos un sustituyente independientemente seleccionado de los grupos alquilo de C1-6, alcoxi de C1-6, OH, halo, CF3, OCF3, SCF3, hidroxi-alquilo de C1-6, alcoxi de C1-4-alquilo de C1-6, y alquilo de C1-4-S-alquilo de C1-4; X es un átomo de S o de O; Y es un átomo de H, un grupo alquilo de C1-6, arilo, het, arilo-alquilo de C1-4 o het-alquilo de C1-4; y n es 1 ó 2, siempre que cuando n sea 1, m sea 0 ó 1 y cuando n sea 2, m sea 0, en la que si m es 0, entonces * representa un centro quiral. Los compuestos de la invención exhiben actividad tanto como agentes inhibidores de la reabsorción de la serotonina como de la noradrenalina, y por lo tanto tienen utilidad en una variedad de áreas terapéuticas, por ejemplo, en la incontinencia urinaria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0314048.0A GB0314048D0 (en) | 2003-06-17 | 2003-06-17 | Novel compounds |
| US49312603P | 2003-08-06 | 2003-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP056232A true ECSP056232A (es) | 2006-04-19 |
Family
ID=33554153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005006232A ECSP056232A (es) | 2003-06-17 | 2005-12-16 | Nuevos compuestos |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7378436B2 (es) |
| EP (1) | EP1638933B1 (es) |
| JP (1) | JP4137159B2 (es) |
| KR (1) | KR100803796B1 (es) |
| AP (1) | AP2005003467A0 (es) |
| AR (1) | AR044715A1 (es) |
| AT (1) | ATE398107T1 (es) |
| AU (1) | AU2004247487B2 (es) |
| BR (1) | BRPI0411594A (es) |
| CA (1) | CA2530159C (es) |
| CY (1) | CY1110434T1 (es) |
| DE (1) | DE602004014372D1 (es) |
| DK (1) | DK1638933T3 (es) |
| EA (1) | EA009881B1 (es) |
| EC (1) | ECSP056232A (es) |
| ES (1) | ES2305776T3 (es) |
| HR (2) | HRP20080339T3 (es) |
| IL (1) | IL172063A0 (es) |
| IS (1) | IS8136A (es) |
| MA (1) | MA27885A1 (es) |
| MX (1) | MXPA05013960A (es) |
| NL (1) | NL1026438C2 (es) |
| NZ (1) | NZ544046A (es) |
| PA (1) | PA8605301A1 (es) |
| PE (1) | PE20050631A1 (es) |
| PL (1) | PL1638933T3 (es) |
| PT (1) | PT1638933E (es) |
| SI (1) | SI1638933T1 (es) |
| TW (1) | TW200505852A (es) |
| UY (1) | UY28360A1 (es) |
| WO (1) | WO2004110995A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1307194T2 (sl) * | 2000-07-31 | 2011-07-29 | Nycomed Danmark Aps | Sestavek fentanila za nazalno dejanje |
| DK1638933T3 (da) * | 2003-06-17 | 2008-07-28 | Pfizer | N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer |
| MX2007004661A (es) | 2004-10-18 | 2007-06-22 | Lilly Co Eli | Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3. |
| GB0425766D0 (en) * | 2004-11-23 | 2004-12-22 | Pfizer Ltd | Novel compounds |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| CA2590226A1 (en) * | 2004-12-14 | 2006-06-22 | Pfizer Limited | N-pyrrolidin-3yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| WO2006064336A2 (en) * | 2004-12-14 | 2006-06-22 | Pfizer Limited | N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| TWI449692B (zh) * | 2005-05-13 | 2014-08-21 | Otsuka Pharma Co Ltd | 吡咯烷化合物（三） |
| EP1893603B1 (en) | 2005-06-02 | 2009-10-14 | F. Hoffmann-La Roche AG | Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists |
| WO2007135530A2 (en) * | 2006-05-22 | 2007-11-29 | Pfizer Limited | Pharmaceutically & veterinarily suitable salt |
| US20080014152A1 (en) * | 2006-07-13 | 2008-01-17 | Di Mauro Thomas M | Intranasal delivery of clenbuterol across the cribriform plate and into the brain |
| JP5219465B2 (ja) * | 2006-11-10 | 2013-06-26 | 大塚製薬株式会社 | 医薬 |
| US20100056497A1 (en) * | 2007-01-31 | 2010-03-04 | Dainippon Sumitomo Pharma Co., Ltd | Amide derivative |
| JP2010189275A (ja) * | 2007-06-14 | 2010-09-02 | Dainippon Sumitomo Pharma Co Ltd | ナフタレン誘導体 |
| US8263652B2 (en) | 2007-10-31 | 2012-09-11 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| EP2243779A4 (en) * | 2007-12-19 | 2011-04-20 | Dainippon Sumitomo Pharma Co | HETEROCYCLIC BICYCLIC DERIVATIVE |
| ES2434250T3 (es) | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compuestos de 3-(fenoxifenilmetil)pirrolidina |
| PT2358675E (pt) | 2008-11-14 | 2012-12-12 | Theravance Inc | Compostos de 4-[2-(2-fluorofenoximetil)fenil]piperidina |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| CA2765527A1 (en) | 2009-06-24 | 2010-12-29 | Satoshi Suetsugu | N-substituted-cyclic amino derivative |
| US7994209B2 (en) * | 2009-07-13 | 2011-08-09 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
| JP5714580B2 (ja) | 2009-07-21 | 2015-05-07 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ３−フェノキシメチルピロリジン化合物 |
| US8778949B2 (en) * | 2010-01-11 | 2014-07-15 | Theravance Biopharma R&D Ip, Llc | 1-(2-phenoxymethylphenyl)piperazine compounds |
| ES2543064T3 (es) * | 2010-03-22 | 2015-08-14 | Theravance Biopharma R&D Ip, Llc | Compuestos de 1-(2-fenoximetilheteroaril)piperidina y piperazina |
| ES2533434T3 (es) | 2010-10-11 | 2015-04-10 | Theravance Biopharma R&D Ip, Llc | Inhibidores de la captación de la serotonina |
| WO2012075239A1 (en) | 2010-12-03 | 2012-06-07 | Theravance, Inc. | Serotonin reuptake inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE138773C (es) | ||||
| US3963745A (en) * | 1972-04-03 | 1976-06-15 | A. H. Robins Company, Incorporated | Method for controlling emesis with N-(1-substituted-3-pyrrolidinyl)benzamides and thiobenzamides |
| US4002757A (en) * | 1974-12-26 | 1977-01-11 | A. H. Robins Company, Incorporated | N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides |
| US4020072A (en) * | 1976-05-04 | 1977-04-26 | E. R. Squibb & Sons, Inc. | 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines |
| GB1574419A (en) * | 1977-11-11 | 1980-09-03 | Anphar Sa | Piperidine compounds |
| CH628885A5 (en) * | 1978-01-01 | 1982-03-31 | Anphar Sa | Piperidine derivative |
| US5130312A (en) * | 1987-07-17 | 1992-07-14 | Janssen Pharmaceutica N.V. | Substituted N-(3-hydroxy-4-piperidinyl)benzamides |
| FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
| WO1997018813A1 (en) | 1995-11-22 | 1997-05-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU4167099A (en) | 1998-06-19 | 2000-01-05 | Nissan Chemical Industries Ltd. | Heterocyclic compounds as hypoglycemic agents |
| US6670299B1 (en) * | 1999-07-03 | 2003-12-30 | Northwestern University | Cyclopentadienyl-containing low-valent early transition metal olefin polymerization catalysts |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| AU2001249091A1 (en) | 2000-03-03 | 2001-09-17 | Eisai Co. Ltd. | Novel methods using cholinesterase inhibitors |
| CN101230034A (zh) * | 2000-03-06 | 2008-07-30 | 阿卡蒂亚药品公司 | 用于治疗5-羟色胺相关性疾病的氮杂环化合物 |
| JP2004509891A (ja) | 2000-09-22 | 2004-04-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 抗糖尿病薬としてのピラゾロピリジンおよびピラゾロピリダジン |
| US20040102431A1 (en) | 2000-09-25 | 2004-05-27 | Christoph Boss | Substituted amino-aza-cycloalkanes useful against malaria |
| WO2003024928A2 (en) | 2001-09-14 | 2003-03-27 | Novo Nordisk A/S | Novel aminoazetidine, -pyrrolidine and -piperidine derivatives |
| EP1442018A1 (en) | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
| GB0128287D0 (en) | 2001-11-26 | 2002-01-16 | Smithkline Beecham Plc | Novel method and compounds |
| CA2490397A1 (en) * | 2002-06-24 | 2003-12-31 | Acadia Pharmaceuticals Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2004009549A2 (en) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| WO2004022536A1 (en) | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| CN1747929B (zh) | 2002-12-20 | 2010-04-28 | 坎莫森特里克斯公司 | 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂 |
| DK1638933T3 (da) * | 2003-06-17 | 2008-07-28 | Pfizer | N-pyrrolidin-3-yl-amid-derivater som serotonin- og noradrenalin-genoptagelses inhibitorer |
-
2004
- 2004-06-07 DK DK04736241T patent/DK1638933T3/da active
- 2004-06-07 CA CA002530159A patent/CA2530159C/en not_active Expired - Fee Related
- 2004-06-07 EA EA200501730A patent/EA009881B1/ru not_active IP Right Cessation
- 2004-06-07 AP AP2005003467A patent/AP2005003467A0/xx unknown
- 2004-06-07 EP EP04736241A patent/EP1638933B1/en not_active Expired - Lifetime
- 2004-06-07 PT PT04736241T patent/PT1638933E/pt unknown
- 2004-06-07 HR HR20080339T patent/HRP20080339T3/xx unknown
- 2004-06-07 BR BRPI0411594-5A patent/BRPI0411594A/pt not_active IP Right Cessation
- 2004-06-07 PL PL04736241T patent/PL1638933T3/pl unknown
- 2004-06-07 NZ NZ544046A patent/NZ544046A/en unknown
- 2004-06-07 DE DE602004014372T patent/DE602004014372D1/de not_active Expired - Lifetime
- 2004-06-07 KR KR1020057024147A patent/KR100803796B1/ko not_active Expired - Fee Related
- 2004-06-07 SI SI200430767T patent/SI1638933T1/sl unknown
- 2004-06-07 AT AT04736241T patent/ATE398107T1/de not_active IP Right Cessation
- 2004-06-07 ES ES04736241T patent/ES2305776T3/es not_active Expired - Lifetime
- 2004-06-07 AU AU2004247487A patent/AU2004247487B2/en not_active Expired - Fee Related
- 2004-06-07 JP JP2006516540A patent/JP4137159B2/ja not_active Expired - Fee Related
- 2004-06-07 MX MXPA05013960A patent/MXPA05013960A/es active IP Right Grant
- 2004-06-07 WO PCT/IB2004/001943 patent/WO2004110995A1/en not_active Ceased
- 2004-06-07 HR HR20050993A patent/HRP20050993A2/hr not_active Application Discontinuation
- 2004-06-14 UY UY28360A patent/UY28360A1/es not_active Application Discontinuation
- 2004-06-14 PE PE2004000590A patent/PE20050631A1/es not_active Application Discontinuation
- 2004-06-16 AR ARP040102082A patent/AR044715A1/es not_active Application Discontinuation
- 2004-06-16 PA PA20048605301A patent/PA8605301A1/es unknown
- 2004-06-16 TW TW093117317A patent/TW200505852A/zh unknown
- 2004-06-17 NL NL1026438A patent/NL1026438C2/nl not_active IP Right Cessation
- 2004-06-17 US US10/872,160 patent/US7378436B2/en not_active Expired - Fee Related
-
2005
- 2005-11-20 IL IL172063A patent/IL172063A0/en unknown
- 2005-11-21 IS IS8136A patent/IS8136A/is unknown
- 2005-12-16 EC EC2005006232A patent/ECSP056232A/es unknown
- 2005-12-16 MA MA28674A patent/MA27885A1/fr unknown
-
2008
- 2008-05-21 US US12/124,755 patent/US20080306123A1/en not_active Abandoned
- 2008-08-14 CY CY20081100869T patent/CY1110434T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP056232A (es) | Nuevos compuestos | |
| UY26727A1 (es) | Derivados de tropano útiles en terapia | |
| AR060489A1 (es) | Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol | |
| NO20092692L (no) | MAPK/ERK kinaseinhibitorer | |
| AR083578A1 (es) | INHIBIDORES DE N/N-LACTAMA ACETIL-CoA CARBOXILASA | |
| JO2935B1 (en) | 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine) | |
| WO2007016392A3 (en) | Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors | |
| NO20065929L (no) | Sykliske amidderivater, deres fremstilling og anvendelse | |
| EA200802389A1 (ru) | Азиридинилэпотилоновые соединения | |
| AR083017A1 (es) | Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol | |
| AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| BRPI0711310B8 (pt) | composto inibidor de p38 map cinase, composição farmacêutica compreendendo o mesmo e uso do mesmo | |
| WO2009118473A3 (fr) | Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique | |
| ATE413882T1 (de) | 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren | |
| MY161403A (en) | 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators | |
| MY146939A (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| AR083832A1 (es) | DERIVADOS DE TETRAHIDROPIRIDO[3,2-F][1,4]OXAZEPIN-8-AMINA PARA EL TRATAMIENTO DE ENFERMEDADES Ab-RELACIONADAS | |
| CO5700747A2 (es) | Piperidinas novedosas como moduladores de quimoquina (ccr) | |
| MXPA06001039A (es) | Derivados de nicotinamida utiles como inhibidores de pde4. | |
| EA200970497A1 (ru) | Производные пиррола, их получение и их применение в терапии | |
| DE60314381D1 (de) | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren | |
| EA201171012A1 (ru) | Производные 5-фторбензотиазолов и 5-фторбензимидазолов, содержащие 6-замещенный триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов met | |
| NO20071230L (no) | Oksazolidinoner inneholdende oksindoler som antibakterielle midler | |
| ATE452636T1 (de) | 3-azabicycloä4.1.0üheptan-derivate zur behandlung von depressionen | |
| CO5660263A2 (es) | Derivados de imidazol heteroaril sustituidos como antagonistas del receptor de glutamato |